

## · 专家述评 ·

李蕴潜, 现任吉林大学第一医院神经肿瘤外科副主任。主任医师、教授、博士研究生导师、神经外科学博士、免疫学博士后。兼任中华医学会神经外科学分会全国委员, 中国胶质瘤协作组、垂体瘤协作组专家委员会委员, 中国抗癌协会委员、中国医师协会神经内镜专业委员会委员、中国研究型医院学会脑神经疾患诊疗学组常务委员, 中国医药教育协会神经外科专业委员会常务委员, 中华医学会、中国医师协会吉林省神经外科专业委员会常务委员, 中华医学会吉林省神经外科青年委员会副主任委员, 吉林省神经外科专业委员会肿瘤学组副组长等职。担任国家自然科学基金评审专家, 《NEUROSURGERY》杂志中文版编委, 《中国卫生标准管理》杂志编委、神经外科学名词编写委员会编委、《中国微侵袭神经外科》杂志、《中华临床医师》杂志等多种期刊审稿专家。



临床专业方向是颅底肿瘤的手术治疗, 年平均手术 400 余例, 均取得良好疗效。共发表包括 SCI 收录的学术论文 110 余篇, 其中以第一作者或通讯作者身份发表 SCI 论文 40 余篇, 主持和参与国家级项目 4 项, 其他省厅级科研项目 15 项, 荣获 2016 年度王忠诚中国神经外科青年医师奖, 多次获得吉林省科技进步二等奖及吉林大学医疗成果奖。

# 脑膜瘤的诊断与治疗

李蕴潜

【关键词】脑膜瘤; 手术治疗; 放射疗法; 化学疗法; 靶向治疗; 分子病理学

中图分类号: R739.41

文献标志码: C

doi: 10.11850/j.issn.1009-122X.2020.04.001

## 【参考文献】

- [1] OSTROM Q T, GITTLEMAN H, XU J, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013 [J]. *Neuro Oncology*, 2016, 18(suppl 5): v1-v75.
- [2] CHRISTENSEN H C, KOSTELJANETZ M, JOHANSEN C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997 [J]. *Neurosurgery*, 2003, 52(6): 1327-1333.
- [3] BALDI I, ENGELHARDT J, BONNET C, et al. Epidemiology of meningiomas [J]. *Neurochirurgie*, 2018, 64(1): 5-14.
- [4] RAUSING A, YBO W, STENFLO J. Intracranial meningioma—a population study of ten years [J]. *Acta Neurol Scand*, 1970, 46(1): 102-110.
- [5] RUBIN G, HERSCOVICI Z, LAVIV Y, et al. Outcome of untreated meningiomas [J]. *Isr Med Assoc J*, 2011, 13(3): 157-160.
- [6] PRESTON D L, RON E, YONEHARA S, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure [J]. *J Natl Cancer Inst*, 2002, 94(20): 1555-1563.
- [7] VIENNE-JUMEAU A, TAFANI C, RICARD D. Environmental risk factors of primary brain tumors: A review [J]. *Rev Neurol (Paris)*, 2019, 175(10): 664-678.
- [8] OSTROM Q T, FAHMIDEH M A, COTE D J, et al. Risk factors for childhood and adult primary brain tumors [J]. *Neuro Oncol*, 2019, 21(11): 1357-1375.
- [9] BIR S C, MAITI T K, BOLLAM P, et al. Felix Platter and a historical perspective of the meningioma [J]. *Clin Neurol Neurosurg*, 2015, 134: 75-78.
- [10] AL-RODHAN N R, LAWS JR E R. Meningioma: a historical study of the tumor and its surgical management [J]. *Neurosurgery*, 1990, 26(5): 832-847.
- [11] GIUFFRE R. Successful radical removal of an intracranial meningioma in 1835 by professor Pecchioli of Siena [J]. *J Neurosurg*, 1984, 60(1): 47-51.
- [12] ANSARI S F, GIANARIS N G, COHEN-GADOL A A. A meningioma and its consequences for American history and the rise of neurosurgery [J]. *J Neurosurg*, 2011, 115(6): 1067-1071.
- [13] CUSHING H. The meningiomas (dural endotheliomas): their source, and favoured seats of origin [J]. *Brain*, 1922, 45(2): 282-316.
- [14] CHEN T, JIANG B, ZHENG Y, et al. Differentiating intracranial solitary fibrous tumor/hemangiopericytoma from meningioma using diffusion-weighted imaging and susceptibility-weighted imaging [J]. *Neuroradiology*, 2019, 62(2): 175-184.
- [15] MITAMURA K, YAMAMOTO Y, NORIKANE T, et al. Correlation of F-FDG and C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed

- intracranial meningiomas [J]. *Ann Nucl Med*, 2018, 32(9): 627-33.
- [16] CLARK V E, ERSON-OMAY E Z, SERIN A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO [J]. *Science (New York, NY)*, 2013, 339(6123): 1077-1080.
- [17] BRASTIANOS P K, HOROWITZ P M, SANTAGATA S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations [J]. *Nature genetics*, 2013, 45(3): 285-289.
- [18] YUZAWA S, NISHIHARA H, TANAKA S. Genetic landscape of meningioma [J]. *Brain Tumor Pathol*, 2016, 33(4): 237-247.
- [19] REUSS D E, PIRO R M, JONES D T, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations [J]. *Acta Neuropathol*, 2013, 125(3): 351-358.
- [20] SAHM F, SCHRIMPF D, OLAR A, et al. TERT promoter mutations and risk of recurrence in meningioma [J]. *J Natl Cancer Inst*, 2016, 108(5): djv377.
- [21] VENGOECHEA J, SLOAN A E, CHEN Y, et al. Methylation markers of malignant potential in meningiomas [J]. *J Neurosurg*, 2013, 119(4): 899-906.
- [22] JAASKELAINEN J, HALTIA M, SERVO A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome [J]. *Surg Neurol*, 1986, 25(3): 233-242.
- [23] GOLDBRUNNER R, MINNITI G, PREUSSER M, et al. EANO guidelines for the diagnosis and treatment of meningiomas [J]. *Lancet Oncol*, 2016, 17(9): e383-e391.
- [24] NATIONAL COMPREHENSIVE CANCER NETWORK. Central nervous system cancers (version 2.2020) [Z/OL]. (2020-4-30) [2020-7-7] [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf).
- [25] MUHR C, GUDJONSSON O, LILJA A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography [J]. *Clin Cancer Res*, 2001, 7(8): 2269-2276.
- [26] JI Y, RANKIN C, GRUNBERG S, et al. Double-blind phase III randomized trial of the antiprogesterin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 [J]. *J Clin Oncol*, 2015, 33(34): 4093-4098.
- [27] GRAILLON T, ROMANO D, DEFILLES C, et al. Octreotide therapy in meningiomas: *in vitro* study, clinical correlation, and literature review [J]. *J Neurosurg*, 2017, 127(3): 660-669.
- [28] LE RHUN E, TAILLIBERT S, CHAMBERLAIN M C. Systemic therapy for recurrent meningioma [J]. *Neurother*, 2016, 16(8): 889-901.
- [29] DASANU C A, ALVAREZ-ARGOTE J, LIMONADI F M, et al. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs [J]. *Expert Opin Biol Ther*, 2019, 19(2): 99-104.
- [30] FURTNER J, SCHOPF V, SEYSTAHL K, et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma [J]. *Neuro Oncology*, 2016, 18(3): 401-407.
- [31] SHIH K C, CHOWDHARY S, ROSENBLATT P, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma [J]. *J Neurooncol*, 2016, 129(2): 281-288.
- [32] KALEY T, BARANI I, CHAMBERLAIN M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: A RANO review [J]. *Neuro Oncol*, 2014, 16(6): 829-840.
- [33] MUTO J, PREVEDELLO D M, DITZEL FILHO L F, et al. Comparative analysis of the anterior transpetrosal approach with the endoscopic endonasal approach to the petroclival region [J]. *J Neurosurg*, 2016, 125(5): 1171-1186.
- [34] PANAGOPOULOS I, GORUNOVA L, LESKE H, et al. Pyrosequencing analysis of MGMT promoter methylation in meningioma [J]. *Cancer Genomics Proteomics*, 2018, 15(5): 379-185.
- [35] WU S, GAVRILOVEC I, DE LA FUENTE M I, et al. ACTR-43. Pilot study of optune (novottf-100a) for recurrent atypical and anaplastic meningioma [J]. *Neuro Oncol*, 2016, 18(suppl\_6): vi11.

(收稿日期:2020-01-06; 修回日期:2020-05-07)